NSG 6005 PHARM MIDTERM EXAM
WITH ALL ANSWERS PROVIDED
A npatient's nnutritional nintake nand nlab nwork nreflect nhypoalbuminemia. nThis
nis ncritical nto nprescribing nbecause: n- ncorrect nanswer-Distribution nof ndrugs
nto ntarget ntissue nmay nbe naffected
Drugs nthat nhave na nsignificant nfirst-pass neffect: n- ncorrect nanswer-Are
nrapidly nmetabolized nby nthe nliver nand nmay nhave nlittle nif nany ndesired
naction
The nroute nof nexcretion nof na nvolatile ndrug nwill nbe: n- ncorrect nanswer-The
nlungs
The npoint nin ntime non nthe ndrug nconcentration ncurve nthat nindicated nthe
nfirst nsign nof na ntherapeutic neffect nis nthe: n- ncorrect nanswer-Onset nof
naction
Factors nthat naffect ngastric ndrug nabsorption ninclude: n- ncorrect nanswer-Lipid
nsolubility nof nthe ndrug
Which none nof nthe nfollowing nstatements nabout nbio navailability nis ntrue? n-
ncorrect nanswer-Bio navailability nissues nare nespecially nimportant nfor ndrugs
nwith nnarrow ntherapeutic nranges nor nsustained nrelease nmechanisms.
, Steady nState nis: n- ncorrect nanswer-When nthe namount nof ndrug nin nthe
nbody nremains nconstant.
The ntime nrequired nfor nthe namount nof ndrug nin nthe nbody nto ndecrease nby
n50% nis ncalled: n- ncorrect nanswer-Half-life
An nadvantage nof nprescribing na nsublingual nmedication nis nthat nthe
nmedication nis: n- ncorrect nanswer-Absorbed nrapidly
Drugs nthat nuse nCYP n3A4 nisoenzymes nfor nmetabolism nmay:
1. nInduce nthe nmetabolism nof nanother ndrug
2. nInhibit nthe nmetabolism nof nanother ndrug
3. nBoth n1 nand n2
4. nNeither n1 nnor n2 n- ncorrect nanswer-BOTH nA nand nB
Induce nthe nmetabolism nof nanother ndrug
Inhibit nthe nmetabolism nof nanother ndrug
A nnurse npractitioner nwould nprescribe nthe nliquid nform nof nibuprofen nfor na
nsix-year-old nbecause: n- ncorrect nanswer-A nsix nyear nold nmay nhave
nproblems nwith nswallowing na npill.
The nfirst nstep nin nthe nprescribing nprocess naccording nto nthe nworld nhealth
norganization nis: n- ncorrect nanswer-diagnosing nthe npatient's nproblem nD
Patient nEducation nregarding nprescribed nmedication nincludes: n- ncorrect
nanswer-Discussion nof nexpected nADRs
Pharmacokinetic nfactors nthat naffect nprescribing ninclude n- ncorrect nanswer-
Bioavalability
Infants nand nyoung nchildren nare nat nhigher nrisk nof nADRs ndue nto n-
ncorrect nanswer-Lack nof nsafety nand nefficacy nstudies nin nthe npediatric
npopulation
The nelderly nare nat nhigh nrisk nof nADRs ndue nto: n- ncorrect nanswer-Age
nrelated ndecrease nin nrenal nfunction
The ntype nof nADR nthat nis nthe nresult nof nan nunwanted nbut notherwise
nnormal npharmacological naction nof na ndrug ngiven nin nthe nusual ntherapeutic
ndoses nis n- ncorrect nanswer-Type nA
A npatient nmay ndevelop nneutropenia nfrom nusing ntypical nSilvadene nfor
nburns. nNeutropenia nis: n- ncorrect nanswer-A ncytoxic nhypersensitivity nreaction
WITH ALL ANSWERS PROVIDED
A npatient's nnutritional nintake nand nlab nwork nreflect nhypoalbuminemia. nThis
nis ncritical nto nprescribing nbecause: n- ncorrect nanswer-Distribution nof ndrugs
nto ntarget ntissue nmay nbe naffected
Drugs nthat nhave na nsignificant nfirst-pass neffect: n- ncorrect nanswer-Are
nrapidly nmetabolized nby nthe nliver nand nmay nhave nlittle nif nany ndesired
naction
The nroute nof nexcretion nof na nvolatile ndrug nwill nbe: n- ncorrect nanswer-The
nlungs
The npoint nin ntime non nthe ndrug nconcentration ncurve nthat nindicated nthe
nfirst nsign nof na ntherapeutic neffect nis nthe: n- ncorrect nanswer-Onset nof
naction
Factors nthat naffect ngastric ndrug nabsorption ninclude: n- ncorrect nanswer-Lipid
nsolubility nof nthe ndrug
Which none nof nthe nfollowing nstatements nabout nbio navailability nis ntrue? n-
ncorrect nanswer-Bio navailability nissues nare nespecially nimportant nfor ndrugs
nwith nnarrow ntherapeutic nranges nor nsustained nrelease nmechanisms.
, Steady nState nis: n- ncorrect nanswer-When nthe namount nof ndrug nin nthe
nbody nremains nconstant.
The ntime nrequired nfor nthe namount nof ndrug nin nthe nbody nto ndecrease nby
n50% nis ncalled: n- ncorrect nanswer-Half-life
An nadvantage nof nprescribing na nsublingual nmedication nis nthat nthe
nmedication nis: n- ncorrect nanswer-Absorbed nrapidly
Drugs nthat nuse nCYP n3A4 nisoenzymes nfor nmetabolism nmay:
1. nInduce nthe nmetabolism nof nanother ndrug
2. nInhibit nthe nmetabolism nof nanother ndrug
3. nBoth n1 nand n2
4. nNeither n1 nnor n2 n- ncorrect nanswer-BOTH nA nand nB
Induce nthe nmetabolism nof nanother ndrug
Inhibit nthe nmetabolism nof nanother ndrug
A nnurse npractitioner nwould nprescribe nthe nliquid nform nof nibuprofen nfor na
nsix-year-old nbecause: n- ncorrect nanswer-A nsix nyear nold nmay nhave
nproblems nwith nswallowing na npill.
The nfirst nstep nin nthe nprescribing nprocess naccording nto nthe nworld nhealth
norganization nis: n- ncorrect nanswer-diagnosing nthe npatient's nproblem nD
Patient nEducation nregarding nprescribed nmedication nincludes: n- ncorrect
nanswer-Discussion nof nexpected nADRs
Pharmacokinetic nfactors nthat naffect nprescribing ninclude n- ncorrect nanswer-
Bioavalability
Infants nand nyoung nchildren nare nat nhigher nrisk nof nADRs ndue nto n-
ncorrect nanswer-Lack nof nsafety nand nefficacy nstudies nin nthe npediatric
npopulation
The nelderly nare nat nhigh nrisk nof nADRs ndue nto: n- ncorrect nanswer-Age
nrelated ndecrease nin nrenal nfunction
The ntype nof nADR nthat nis nthe nresult nof nan nunwanted nbut notherwise
nnormal npharmacological naction nof na ndrug ngiven nin nthe nusual ntherapeutic
ndoses nis n- ncorrect nanswer-Type nA
A npatient nmay ndevelop nneutropenia nfrom nusing ntypical nSilvadene nfor
nburns. nNeutropenia nis: n- ncorrect nanswer-A ncytoxic nhypersensitivity nreaction
